Use of Somatropin in Turner Syndrome

• Status: Completed
• Trial end date: 2004-04-11
• Target enrollment: 0
• Participant gender: Female

Summary

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Turner Syndrome

• Not previously treated with growth hormone or androgen

• Well-documented height over the previous 12 months

• Informed consent of parents (and child if appropriate)

Exclusion Criteria:

• Growth hormone (GH) deficiency based on a GH stimulation test